宏源药业
(301246)
| 流通市值：24.29亿 | | | 总市值：60.36亿 |
| 流通股本：1.61亿 | | | 总股本：4.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 433,455,447.87 | 1,770,723,711.98 | 1,322,234,413.75 | 898,125,095.81 |
| 营业收入 | 433,455,447.87 | 1,770,723,711.98 | 1,322,234,413.75 | 898,125,095.81 |
| 二、营业总成本 | 416,830,661.03 | 1,712,679,177.05 | 1,265,739,711.39 | 849,871,656.81 |
| 营业成本 | 376,585,908.33 | 1,554,957,164.84 | 1,156,434,332.78 | 772,818,932.43 |
| 税金及附加 | 3,319,570.38 | 10,127,284.25 | 7,021,259.82 | 4,738,652.29 |
| 销售费用 | 8,092,985.15 | 37,331,641.46 | 26,484,405.67 | 18,176,756.12 |
| 管理费用 | 12,614,316.94 | 54,053,147.73 | 34,686,204.44 | 25,689,602.64 |
| 研发费用 | 16,336,047.27 | 59,177,990.33 | 41,660,613.38 | 30,793,313.49 |
| 财务费用 | -118,167.04 | -2,968,051.56 | -547,104.7 | -2,345,600.16 |
| 其中:利息费用 | 3,070,471.12 | 11,999,930.57 | 8,920,697.27 | 5,897,277.75 |
| 其中:利息收入 | 2,850,803.38 | 11,071,461.32 | 8,244,347.52 | 5,669,319.59 |
| 加:公允价值变动收益 | 3,748,778.09 | 3,817,511.65 | 734,829.45 | -460,372.1 |
| 加:投资收益 | -1,756,535.48 | 3,052,812.1 | 1,259,863.6 | 3,012,409.92 |
| 资产处置收益 | 58,294.69 | 533,612.43 | 94,503.36 | 75,199.82 |
| 资产减值损失(新) | -10,596,812.38 | -34,813,418.11 | -23,384,990.53 | -14,196,915.21 |
| 信用减值损失(新) | -1,097,218.04 | -1,620,390.8 | -1,547,449.72 | -2,121,421.93 |
| 其他收益 | 5,274,788.81 | 31,029,964.4 | 12,027,805.99 | 7,197,894.89 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 12,256,082.53 | 60,044,626.6 | 45,679,264.51 | 41,760,234.39 |
| 加:营业外收入 | 66,650.74 | 128,926.99 | 88,115.74 | 59,638.34 |
| 减:营业外支出 | 573,259.4 | 482,678.11 | 400,519.5 | 400,510.99 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 11,749,473.87 | 59,690,875.48 | 45,366,860.75 | 41,419,361.74 |
| 减:所得税费用 | 2,926,078.94 | 8,229,119.75 | 9,224,615.44 | 5,609,751.05 |
| 六、净利润 | 8,823,394.93 | 51,461,755.73 | 36,142,245.31 | 35,809,610.69 |
| 持续经营净利润 | 8,823,394.93 | 51,461,755.73 | 36,142,245.31 | 35,809,610.69 |
| 归属于母公司股东的净利润 | 8,886,072.24 | 51,465,054.11 | 36,142,245.31 | 35,809,610.69 |
| 少数股东损益 | -62,677.31 | -3,298.38 | - | - |
| (一)基本每股收益 | 0.02 | 0.13 | 0.09 | 0.09 |
| (二)稀释每股收益 | 0.02 | 0.13 | 0.09 | 0.09 |
| 九、综合收益总额 | 8,823,394.93 | 51,461,755.73 | 36,142,245.31 | 35,809,610.69 |
| 归属于母公司股东的综合收益总额 | 8,886,072.24 | 51,465,054.11 | 36,142,245.31 | 35,809,610.69 |
| 归属于少数股东的综合收益总额 | -62,677.31 | -3,298.38 | - | - |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-25 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |